GR1008865B - Μεθοδος για την αυξηση της υδατοδιαλυτοτητας της σιλιμπινινης ως συστατικου της σιλυμαρινης - Google Patents

Μεθοδος για την αυξηση της υδατοδιαλυτοτητας της σιλιμπινινης ως συστατικου της σιλυμαρινης

Info

Publication number
GR1008865B
GR1008865B GR20150100312A GR20150100312A GR1008865B GR 1008865 B GR1008865 B GR 1008865B GR 20150100312 A GR20150100312 A GR 20150100312A GR 20150100312 A GR20150100312 A GR 20150100312A GR 1008865 B GR1008865 B GR 1008865B
Authority
GR
Greece
Prior art keywords
silibinin
silymarin
increasing
component
water solubility
Prior art date
Application number
GR20150100312A
Other languages
English (en)
Inventor
Δημητριος Μιχαηλ Ρεκκας
Ολγα Ανδρεα Στρατηγοπουλου
Γεωργια Νικολαου Βαλσαμη
Αγγελος Αντωνιου Καρατζας
Original Assignee
Δημητριος Μιχαηλ Ρεκκας
Ολγα Ανδρεα Στρατηγοπουλου
Γεωργια Νικολαου Βαλσαμη
Αγγελος Αντωνιου Καρατζας
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Δημητριος Μιχαηλ Ρεκκας, Ολγα Ανδρεα Στρατηγοπουλου, Γεωργια Νικολαου Βαλσαμη, Αγγελος Αντωνιου Καρατζας filed Critical Δημητριος Μιχαηλ Ρεκκας
Priority to GR20150100312A priority Critical patent/GR1008865B/el
Publication of GR1008865B publication Critical patent/GR1008865B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία μέθοδο in situ παραγωγής συμπλοκών εγκλεισμού (SLB-CD) της σιλιμπινίνης (SLB), δηλαδή του κύριου δραστικού συστατικού του στερεού εκχυλίσματος (σιλυμαρίνη, SLM) που προκύπτει από τους σπόρους του γαϊδουράγκαθου (Milk Thistle), με κυκλοδεξτρίνες (CD), κατά τη διεργασία υγρής κοκκοποίησης. Τα σύμπλοκα εγκλεισμού, τα οποία παρασκευάζονται με τη μέθοδο της παρούσας εφεύρεσης, είναι σταθερά και εμφανίζουν υψηλότερο αθροιστικό ποσοστό και ταχύτερο ρυθμό διάλυσης (αποδέσμευσης), της περιεχόμενης στο σύμπλοκο σιλιμπινίνης, σε σχέση με το αντίστοιχο αθροιστικό ποσοστό και ρυθμό διάλυσης της περιεχόμενης σιλιμπινίνης στο στερεό εκχύλισμα γαϊδουράγκαθου.
GR20150100312A 2015-06-23 2015-06-23 Μεθοδος για την αυξηση της υδατοδιαλυτοτητας της σιλιμπινινης ως συστατικου της σιλυμαρινης GR1008865B (el)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20150100312A GR1008865B (el) 2015-06-23 2015-06-23 Μεθοδος για την αυξηση της υδατοδιαλυτοτητας της σιλιμπινινης ως συστατικου της σιλυμαρινης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20150100312A GR1008865B (el) 2015-06-23 2015-06-23 Μεθοδος για την αυξηση της υδατοδιαλυτοτητας της σιλιμπινινης ως συστατικου της σιλυμαρινης

Publications (1)

Publication Number Publication Date
GR1008865B true GR1008865B (el) 2016-10-06

Family

ID=55174660

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20150100312A GR1008865B (el) 2015-06-23 2015-06-23 Μεθοδος για την αυξηση της υδατοδιαλυτοτητας της σιλιμπινινης ως συστατικου της σιλυμαρινης

Country Status (1)

Country Link
GR (1) GR1008865B (el)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0422497A2 (en) * 1989-10-09 1991-04-17 IBI- Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. Inclusion complexes with silybinin, their preparation and pharmaceutical compositions containing them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0422497A2 (en) * 1989-10-09 1991-04-17 IBI- Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. Inclusion complexes with silybinin, their preparation and pharmaceutical compositions containing them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. GHOSH ET AL: "Preparation and Evaluation of Silymarin [beta]-cyclodextrin Molecular Inclusion Complexes", JOURNAL OF YOUNG PHARMACISTS, vol. 3, no. 3, 1 July 2011 (2011-07-01), India, pages 205 - 210, XP055267088, ISSN: 0975-1483, DOI: 10.4103/0975-1483.83759 *
TAHSIN F. KELLICI ET AL: "Investigation of the Interactions of Silibinin with 2-Hydroxypropyl-[beta]-cyclodextrin through Biophysical Techniques and Computational Methods", MOLECULAR PHARMACEUTICS, vol. 12, no. 3, 9 February 2015 (2015-02-09), US, pages 954 - 965, XP055266118, ISSN: 1543-8384, DOI: 10.1021/mp5008053 *

Similar Documents

Publication Publication Date Title
MY206637A (en) Generation of peroxyformic acid through polyhydric alcohol formate
PH12016502586A1 (en) Lipid comprising docosapentaenoic acid
HRP20220075T1 (hr) Tekuća formulacija koja sadrži nikotin za aerosolnu primjenu
ZA201802451B (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2017004579A (es) Estructuras fibrosas solubles y metodos para fabricarlas.
MA43297A (fr) Semelle, en particulier pour chaussures
HK1246800A1 (zh) 用於营养组合物的寡糖组合物和其制造方法
ZA201606125B (en) Method for producing vitamine e-enriched, especially tocotrienol-enriched, compositions from natural oils
MX362418B (es) Composiciones aglutinantes para tabletas.
CA2947310C (en) Microparticles for treating renal cell carcinoma
PH12014502082A1 (en) Liquid tobacco compositions
IN2014MU00675A (el)
IN2014CH00151A (el)
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
GR1008865B (el) Μεθοδος για την αυξηση της υδατοδιαλυτοτητας της σιλιμπινινης ως συστατικου της σιλυμαρινης
MY188557A (en) Lipid comprising docosapentaenoic acid
MX2017003609A (es) Inhibidor de corrosion biologica para metales.
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
MX2016015846A (es) Composicion en polvo de sorbitol y goma de mascar que comprende esta composicion.
IN2013CH04635A (el)
NZ726934A (en) Food compositions comprising tungsten (vi) salts
JP2015062178A5 (el)
AU2014903593A0 (en) FormTeam provides an on-line, real-time team formation solution for clubs, their members & other organisations that want to form teams prior to player & team registration.
Hoshyaripour Volcanic ash particles hold clues to their history and effects
MY187412A (en) Energy recovery in a method for preparing 1,3,5-trioxane

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20161118